Comparative Pharmacology
Head-to-head clinical analysis: ANGIO CONRAY versus ANGIOVIST 282.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIO CONRAY versus ANGIOVIST 282.
ANGIO-CONRAY vs ANGIOVIST 282
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angio-Conray (iothalamate meglumine) is a radiopaque contrast agent that attenuates X-rays, providing vascular opacification for angiographic procedures.
Angiovist 282 (diatrizoate meglumine and diatrizoate sodium) is a radiographic contrast agent that contains iodine, which attenuates X-rays, allowing visualization of vascular structures and organs. It increases the contrast between blood vessels and surrounding tissues by absorbing X-rays.
Intravenous: 0.5-1 mL/kg (maximum 100 mL) of a 60% solution for computed tomography; intra-arterial: varies by procedure, typically 5-80 mL of 60% or 76% solution.
Iohexol (ANGIOVIST 282) is a nonionic iodinated contrast medium. Typical adult dose: 50-200 mL intravenously or intra-arterially, depending on procedure (e.g., CT: 75-150 mL IV).
None Documented
None Documented
Terminal elimination half-life: 1-2 hours; prolonged in renal impairment.
Terminal elimination half-life: 1.5–2 hours in patients with normal renal function; prolonged in renal impairment.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Renal excretion via glomerular filtration; unchanged drug: >95% within 24 hours. Biliary/fecal: <5%.
Category C
Category C
Contrast Agent
Contrast Agent